A phase I clinical trial of MV-CEA for the treatment of recurrent glioblastoma multiforme found no dose limiting toxicities with MV-CEA doses up to 2×107 TCID50 (NCT00390299) (136). The gene discussed is CEACAM5; the disease is glioblastoma.